ECT Pulse Amplitude and Medial Temporal Lobe Engagement

NCT02999269 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-07-24

Study results available
· View outcomes & findings →

Summary

Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antidepressant effect of ECT, many patients experience transient memory impairment. This investigation will examine the impact of one ECT parameter (pulse amplitude or current) on brain changes (structure of connections within the brain) and clinical outcomes. The goal of this investigation is to determine the optimal parameter for an individual patient that will maintain the clinical response (reduce depression severity) and minimize side effects (eliminate memory issues related to treatment).

Conditions

Interventions

DEVICE

MECTA Spectrum 5000Q Amplitude

Current

Sponsors & Collaborators

  • The Mind Research Network

    collaborator OTHER
  • University of Texas

    collaborator OTHER
  • National Institute of Mental Health (NIMH)

    collaborator NIH
  • University of New Mexico

    lead OTHER

Principal Investigators

  • Chris Abbott, MD · University of New Mexico

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-03-23
Completion
2020-03-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02999269 on ClinicalTrials.gov